Age-dependent acquisition of IgG antibodies to
IgG antibodies
Kenya
Shigella flexneri
Shigella sonnei
sero-prevalence
serotype
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
20
11
2023
accepted:
12
01
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
epublish
Résumé
Shigellosis mainly affects children under 5 years of age living in low- and middle-income countries, who are the target population for vaccination. There are, however, limited data available to define the appropriate timing for vaccine administration in this age group. Information on antibody responses following natural infection, proxy for exposure, could help guide vaccination strategies. We undertook a retrospective analysis of antibodies to five of the most prevalent A total of 474 samples, one for each participant, were analyzed: Nairobi ( Children living in low- and middle-income settings such as Kenya are exposed to
Sections du résumé
Background
UNASSIGNED
Shigellosis mainly affects children under 5 years of age living in low- and middle-income countries, who are the target population for vaccination. There are, however, limited data available to define the appropriate timing for vaccine administration in this age group. Information on antibody responses following natural infection, proxy for exposure, could help guide vaccination strategies.
Methods
UNASSIGNED
We undertook a retrospective analysis of antibodies to five of the most prevalent
Results
UNASSIGNED
A total of 474 samples, one for each participant, were analyzed: Nairobi (
Conclusion
UNASSIGNED
Children living in low- and middle-income settings such as Kenya are exposed to
Identifiants
pubmed: 38361949
doi: 10.3389/fimmu.2024.1340425
pmc: PMC10867106
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1340425Informations de copyright
Copyright © 2024 Kapulu, Muthumbi, Otieno, Rossi, Ferruzzi, Necchi, Acquaviva, Martin, Orindi, Mwai, Kibet, Mwanzu, Bigogo, Verani, Mbae, Nyundo, Agoti, Nakakana, Conti, Bejon, Kariuki, Scott, Micoli and Podda.
Déclaration de conflit d'intérêts
Authors OR, PF, FN, AA, UN, VC, and FM are employees of GSK group of companies. LM and AP were employees of GSK group of companies when the study was performed. LM is currently employed by U.S. Pharmacopeia Convention. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.